Motor neuropathy due to docetaxel and paclitaxel
- 1 July 1996
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 47 (1) , 115-118
- https://doi.org/10.1212/wnl.47.1.115
Abstract
Paclitaxel and docetaxel are novel chemotherapeutic agents that promote the polymerization and inhibit the depolymerization of microtubules.Sensory neuropathy is common with these agents, particularly paclitaxel. We evaluated 64 patients treated with these drugs; 54 were followed prospectively. Eleven (17%, including six of the 54 prospectively followed patients) developed muscle weakness that was predominantly proximal. The weakness was idiosyncratic, occurring at any stage of treatment, had a variable course, and was reversible upon cessation of drug. All patients developed symptoms or signs of taxane-induced sensory neuropathy. Weakness was likely neuropathic in origin; electrodiagnostic studies suggested a distal axonopathy in some patients and proximal denervation (anterior horn cell or nerve root) in others. NEUROLOGY 1996;47: 115-118Keywords
This publication has 8 references indexed in Scilit:
- A new look and feelNeurology, 1996
- Intravesical therapy for superficial bladder cancer: is it a wash?Journal of Clinical Oncology, 1994
- Cerebellar control of movementAnnals of Neurology, 1994
- Gene therapy for duchenne dystrophyAnnals of Neurology, 1993
- The role of prophylactic cranial irradiation in the management of small cell lung cancerCancer Treatment Reviews, 1993
- Myelosuppression and "conventional" chemotherapy: what price, what benefit?Journal of Clinical Oncology, 1993
- In This IssueJNCI Journal of the National Cancer Institute, 1991
- Why has so much chemotherapy done so little in head and neck cancer?Journal of Clinical Oncology, 1987